Author (Corporate) | European Medicines Agency |
---|---|
Series Title | Press Release |
Series Details | EMA/804365/2010 (10.12.10) |
Publication Date | 10/12/2010 |
Content Type | News |
The European Medicines Agency (EMA) was informed, in December 2010, of Pfizer’s decision to voluntarily withdraw Thelin from the market worldwide further to new information on two cases of fatal liver injury. Pfizer had also decided to discontinue all ongoing clinical trials. Thelin, which contains the active substance sitaxentan, has been authorised in the European Union (EU) since 2006 for the treatment of pulmonary arterial hypertension. |
|
Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/12/news_detail_001161.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp |
Related Links |
|
Subject Categories | Health |
Countries / Regions | Europe |